In surprise, FDA adcomm votes unanimously in favor of bluebird's gene therapy for rare disease even with safety concerns
In the first day of a two-day meeting, the FDA’s Cellular, Tissue and Gene Therapies advisory committee on Thursday gave a big thumbs up to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
